Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 09/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -34.49% | 39.46% | 39.46% | 45.94% |
| Total Depreciation and Amortization | -- | -27.22% | -21.13% | -20.62% | -14.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 491.23% | -79.81% | -79.92% | -80.19% |
| Change in Net Operating Assets | -- | 65.86% | -96.39% | -96.39% | 16.06% |
| Cash from Operations | -- | 22.06% | 28.94% | 28.94% | 43.64% |
| Capital Expenditure | -- | -- | 25.00% | 25.00% | 25.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 25.00% | 25.00% | 25.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 461.14% | -415.25% | 8.47% | 0.85% |
| Issuance of Common Stock | -- | -83.35% | -66.71% | -83.35% | -100.00% |
| Repurchase of Common Stock | -- | 51.18% | -427.58% | -427.58% | -427.58% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 427.58% | 427.58% | 427.58% |
| Cash from Financing | -- | -52.80% | -69.09% | -69.09% | -91.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -332.64% | -500.00% | -500.00% | -84.80% |